[Clinical studies on sulbactam/cefoperazone in the field of obstetrics and gynecology].
Sulbactam (SBT), a new beta-lactamase inhibitor, in combination with cefoperazone (CPZ) to 1 to 1 was clinically studied in the field of obstetrics and gynecology. SBT/CPZ was administered to 13 subjects at a daily dose of 2 g in 2 divided dose by intravenous infusion for 4-6 days. The subjects were patients with the following infections: 2 of intrauterine infections, 5 of intrapelvic infections, 4 of adnexitis and 2 of vulvar infections. The overall clinical efficacy was good in all. Neither adverse reactions nor abnormal laboratory findings were observed in any of the cases.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002438:Cefoperazone / Q000008:administration & dosage*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D010397:Penicillanic Acid / Q000008:administration & dosage*; D011247:Pregnancy; D013407:Sulbactam; D065093:beta-Lactamase Inhibitors
D004338:Drug Combinations; D065093:beta-Lactamase Inhibitors; D002438:Cefoperazone; D010397:Penicillanic Acid; D013407:Sulbactam